SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is facing significant volatility as investors react to reports that Meta is exploring a cloud business to monetize its excess AI compute capacity. While some market participants fear this signals increased competition and potential oversupply, others view the pullback as an overreaction, emphasizing that CoreWeave's long-term infrastructure contracts remain robust and that underlying AI demand remains tightly supply-constrained.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is surging as investors react to reports that the company plans to monetize its massive AI infrastructure by selling excess compute capacity to external customers. While the news triggered a sharp sell-off in smaller neocloud and semiconductor peers due to fears of increased competition, the broader community is debating whether this initiative is a strategic pivot to boost ROI or a sign of an overbuilt AI infrastructure market.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group stock is facing significant downward pressure following reports that Meta Platforms plans to develop its own cloud business to monetize excess AI compute capacity. Investors are actively debating whether this news signifies a structural threat to the neocloud business model or if it is merely a market overreaction that ignores Nebius's existing multi-billion dollar capacity agreements and the broader, supply-constrained reality of the AI infrastructure sector.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant market interest driven by recent FDA approvals for its tumor-only diagnostic platform and strategic partnerships, which have bolstered the narrative of the company as an emerging infrastructure leader in precision medicine. While community members debate the stock's high short interest and institutional accumulation, sentiment remains sharply divided between those betting on long-term data-moat potential and those skeptical of recent technical volatility.

Jack in the Box, Inc. engages in the provision of developing, operating, and franchising a chain of quick-service and fast-casual restaurants. It operates through the Jack in the Box and Del Taco segments. The Jack in the Box segment offers a selection of distinctive products including classic burgers and other product lines such as Buttery Jack Burgers. The company was founded by Robert Oscar Peterson in 1951 and is headquartered in San Diego, CA.

Jack In The Box, Inc.

Jack in the Box is generating significant retail interest as a high-conviction short-squeeze candidate, driven by its exceptionally small public float and high short interest that has captured the attention of traders mirroring the mechanics of past meme-stock rallies. The community is actively debating the stock's turnaround potential and squeeze viability, with many comparing it to other fast-food plays while discussing the impact of management's operational shifts and debt restructuring plans.

Constellation Energy Corp. engages in the generation, supply, and marketing of clean electricity, and renewable energy products and solutions. The firm also offers wholesale energy, retail products and services. It operates under the following geographical segments: Mid-Atlantic, Midwest, New York, Electric Reliability Council of Texas (ERCOT), and Other Power Regions Segment. The company was founded in 1960 and is headquartered in Baltimore, MD.

Constellation Energy Corporation

Constellation Energy is currently drawing significant investor interest as a core play on the explosive AI-driven electricity demand cycle, with community members actively debating its valuation following a sharp recent pullback. Despite volatility stemming from structural share lock-up expirations and sector-wide sentiment shifts, the consensus among long-term holders remains focused on its unmatched nuclear fleet and strategic, long-term power agreements with major tech hyperscalers.

Oscar Health, Inc. is a healthcare insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is currently trending as investors focus on its strong multi-month trend and breakout potential following significant insider accumulation by management. The community is actively discussing the company's improved fundamental execution and its potential for a sustained re-rating as healthcare sentiment pivots from pessimism to growth.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is currently in the spotlight as investors weigh its aggressive transition from a legacy telecommunications carrier to an AI-focused infrastructure and Network-as-a-Service (NaaS) provider. While the stock has faced recent volatility, the community is actively debating the significance of its strategic revenue growth, the potential impact of the Alkira acquisition, and the long-term role of its fiber network in supporting the surging demand for AI data center connectivity.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is experiencing strong bullish momentum, driven by institutional backing and optimistic analyst price target revisions, with the community actively speculating on a potential short squeeze fueled by elevated short interest. Investors are focusing on the company's expansion into branded weight-loss distribution and the upcoming FDA peptide advisory committee meeting as key catalysts for potential further growth.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Walt Disney is currently trending as investors weigh strong box office performance from the Toy Story franchise against persistent community frustration regarding stagnant long-term share performance and management's strategic direction. While some analysts maintain a bullish outlook citing potential park monetization and streaming growth, retail sentiment remains sharply divided over the company's valuation, park pricing, and ongoing corporate governance controversies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why

COLL gains momentum as strong Jornay PM growth and the Azstarys acquisition boosted 2026 guidance, strengthening its ADHD franchise and revenue outlook.

Bull of the Day: Neurocrine Biosciences (NBIX)

Neurocrine Biosciences (NBIX) has quietly become one of biotech's strongest earnings stories.

Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Beat Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of +23.94% and +7.01%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Collegium Pharmaceutical (COLL) Q1 Earnings Expected to Decline

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Collegium Pharmaceutical (COLL) to Release Quarterly Earnings on Thursday

Collegium Pharmaceutical (NASDAQ:COLL) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...

Q1 EPS Estimate for Collegium Pharmaceutical Cut by Analyst

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) - Investment analysts at HC Wainwright lowered their Q1 2026 earnings estimates for Collegium Pharmaceutical in a research note issued on...

Equities Analysts Offer Predictions for COLL Q2 Earnings

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) - Equities research analysts at HC Wainwright dropped their Q2 2026 earnings per share (EPS) estimates for Collegium Pharmaceutical in a...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven research firms that are presently covering the stock...

Collegium Pharmaceutical, Inc. is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. The firm has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

Collegium Pharmaceutical Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

COLLCollegium Pharmaceutical Inc

Latest COLL News